Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro
Diabetic retinopathy (DR) is a complication of diabetes and a leading cause of blindness in adults. Studies have shown that glucagon-like peptide-1 (GLP-1) exerts a protective effect on patients with DR. Here, we investigated the protective effects of Exendin-4, a GLP-1 analogue, on DR. We established a high-glucose-induced HREC cell model and an STZ-induced rat DR Model to study the effect of Exendin-4 in DR in vitro and in vivo. The qRT-PCR, CCK-8, TUNEL, western blotting, tube formation assays, and ELISA were performed. In addition, we overexpressed TGFB2 to observe whether the protective effect of Exendin-4 was reversed. Our results showed that Exendin-4 inhibited the progression of DR. Furthermore, the protective effect of Exendin-4 was suppressed in cells overexpressing TGFB2. Our findings suggest that Exendin-4 may be involved in the regulation of TGFB2 expression levels to inhibit DR. These results indicate that Exendin-4 could be an effective therapy for DR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Archives of physiology and biochemistry - (2023) vom: 03. Nov., Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Jufen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/13813455.2023.2274279 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364128690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364128690 | ||
| 003 | DE-627 | ||
| 005 | 20231226094806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13813455.2023.2274279 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM364128690 | ||
| 035 | |a (NLM)37920998 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Jufen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Diabetic retinopathy (DR) is a complication of diabetes and a leading cause of blindness in adults. Studies have shown that glucagon-like peptide-1 (GLP-1) exerts a protective effect on patients with DR. Here, we investigated the protective effects of Exendin-4, a GLP-1 analogue, on DR. We established a high-glucose-induced HREC cell model and an STZ-induced rat DR Model to study the effect of Exendin-4 in DR in vitro and in vivo. The qRT-PCR, CCK-8, TUNEL, western blotting, tube formation assays, and ELISA were performed. In addition, we overexpressed TGFB2 to observe whether the protective effect of Exendin-4 was reversed. Our results showed that Exendin-4 inhibited the progression of DR. Furthermore, the protective effect of Exendin-4 was suppressed in cells overexpressing TGFB2. Our findings suggest that Exendin-4 may be involved in the regulation of TGFB2 expression levels to inhibit DR. These results indicate that Exendin-4 could be an effective therapy for DR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetic retinopathy | |
| 650 | 4 | |a Exendin-4 | |
| 650 | 4 | |a GLP-1 | |
| 700 | 1 | |a Wang, Huijing |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Cuiting |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of physiology and biochemistry |d 1997 |g (2023) vom: 03. Nov., Seite 1-10 |w (DE-627)NLM075599813 |x 1744-4160 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:11 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13813455.2023.2274279 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 11 |h 1-10 | ||